Virus-Like Particle Vaccines
The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they in...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04177naaaa2201117uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_69086 | ||
| 005 | 20210501 | ||
| 020 | |a books978-3-03943-075-8 | ||
| 020 | |a 9783039430741 | ||
| 020 | |a 9783039430758 | ||
| 024 | 7 | |a 10.3390/books978-3-03943-075-8 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a H |2 bicssc | |
| 072 | 7 | |a JFFP |2 bicssc | |
| 100 | 1 | |a Bachmann, Martin F |4 edt | |
| 700 | 1 | |a Vogel, Monique |4 edt | |
| 700 | 1 | |a Bachmann, Martin F |4 oth | |
| 700 | 1 | |a Vogel, Monique |4 oth | |
| 245 | 1 | 0 | |a Virus-Like Particle Vaccines |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (262 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Humanities |2 bicssc | |
| 650 | 7 | |a Social interaction |2 bicssc | |
| 653 | |a virus-like particle | ||
| 653 | |a influenza A(H1N1)pdm09 | ||
| 653 | |a vaccination | ||
| 653 | |a pregnant women | ||
| 653 | |a antibody titers | ||
| 653 | |a norovirus | ||
| 653 | |a VLP | ||
| 653 | |a vaccine | ||
| 653 | |a genotype | ||
| 653 | |a pre-existing immunity | ||
| 653 | |a cross-reactivity | ||
| 653 | |a blocking antibodies | ||
| 653 | |a original antigenic sin (OAS) | ||
| 653 | |a HPVs | ||
| 653 | |a vaccines | ||
| 653 | |a virus-like particles (VLPs) | ||
| 653 | |a minor capsid protein (L2) | ||
| 653 | |a HCMV | ||
| 653 | |a cytomegalovirus | ||
| 653 | |a nanoparticle | ||
| 653 | |a immune response | ||
| 653 | |a Sudan virus | ||
| 653 | |a mice | ||
| 653 | |a horse | ||
| 653 | |a purified IgG | ||
| 653 | |a long-lived plasma cells | ||
| 653 | |a antibodies | ||
| 653 | |a multivalency | ||
| 653 | |a virus-like particles | ||
| 653 | |a antigenic analysis | ||
| 653 | |a epitope characterization | ||
| 653 | |a hepatitis E vaccine | ||
| 653 | |a serological evaluation | ||
| 653 | |a virion-like epitopes | ||
| 653 | |a well-characterized vaccines | ||
| 653 | |a hepatitis B virus | ||
| 653 | |a surface (envelope) antigen | ||
| 653 | |a sub-viral particle | ||
| 653 | |a capsid | ||
| 653 | |a antigen display | ||
| 653 | |a platform | ||
| 653 | |a viral quantification | ||
| 653 | |a NTA | ||
| 653 | |a flow virometry | ||
| 653 | |a SRFM | ||
| 653 | |a cryo-TEM | ||
| 653 | |a SEM | ||
| 653 | |a plant virus | ||
| 653 | |a virus-like | ||
| 653 | |a vaccine platform | ||
| 653 | |a epitope | ||
| 653 | |a antigen | ||
| 653 | |a cat allergy | ||
| 653 | |a Fel d 1 | ||
| 653 | |a HypoCat™ | ||
| 653 | |a IL-13 | ||
| 653 | |a interleukin-13 | ||
| 653 | |a Tfh cells | ||
| 653 | |a cancer | ||
| 653 | |a immunotherapy | ||
| 653 | |a H7N9 | ||
| 653 | |a pandemic influenza A | ||
| 653 | |a avian flu | ||
| 653 | |a IAV | ||
| 653 | |a VLP vaccine | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2855 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/69086 |7 0 |z DOAB: description of the publication |